KDRTV News -An Abstract from a scientific approach to treat HIV and AIDS
AIDS (acquired immune deficient syndrome) is a deadly human viral infectious disease caused by HIV (human immune-deficient virus) infection. Almost every AIDS patient losses his/her life before mid 1990s. AIDS was once the 1st disease killer in US (1993). After one decade hard work, antiviral drug cocktails-high active anti-retroviral therapy (HAART) have been invented for almost all HIV infection treatments. Due to the invention of HAART, 80-90% HIV/AIDS patients still effectively response to HAART for deadly AIDS episode controls and life saving. Yet, this type of HIV therapeutics is incurable. HIV/AIDS patients need to take HAART medications regularly and even life-long. To counteract this therapeutic drawback, more revolutionary efforts (different angles of therapeutic modes/attempts) are urgently needed. In this article, the major progresses and drawbacks of HIV/AIDS chemotherapy (HAART) to HIV/AIDS patients have been discussed. Future trends (updating pathogenesis study, next generations of drug developments, new drug target discovery, different scientific disciplinary and so on) are highlighted.
Keywords: HAART; HIV cure; HIV latency; HIV reservoirs; antiviral therapy; biotherapy; drug delivery system; integrase inhibitors; medicinal chemistry; pharmacogenomics.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
- New Perspectives of HIV/AIDS Therapy Study.Lu DY, Lu TR, Che JY, Wu HY, Xu B.Recent Pat Antiinfect Drug Discov. 2014;9(2):112-20. doi: 10.2174/1574891×10666150109115402.PMID: 25578060
- HIV/AIDS Curable Study: New Forms of Therapeutic Trinity.Lu DY, Lu TR, Wu HY, Yarla NS, Ding J, Xu B.Recent Pat Antiinfect Drug Discov. 2018;13(3):217-227. doi: 10.2174/1574891X13666181026094526.PMID: 30362422
- Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.Arici C, Ripamonti D, Ravasio V, Maggiolo F, Rizzi M, Finazzi MG, Suter F.Int J STD AIDS. 2001 Sep;12(9):573-81. doi: 10.1258/0956462011923741.PMID: 11516366
- Adherence to anti-retroviral therapy and its determinants in HIV/AIDS patients: a review.Emamzadeh-Fard S, Fard SE, SeyedAlinaghi S, Paydary K.Infect Disord Drug Targets. 2012 Oct;12(5):346-56. doi: 10.2174/187152612804142251.PMID: 23017163 Review.
- Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.Voshavar C.Curr Top Med Chem. 2019;19(18):1571-1598. doi: 10.2174/1568026619666190619115243.PMID: 31237209 Review.
Cited by
- Evolution Driven By A Varying Host Environment Selects For Distinct HIV-1 Entry Phenotypes and Other Informative Variants.Zhou S, Long N, Swanstrom R.Front Virol. 2023;3:1291996. doi: 10.3389/fviro.2023.1291996. Epub 2023 Nov 16.PMID: 38239974 Free PMC article.
- The Influence of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial Activity, Lipid Content, and Fatty-Acid-Binding Protein Levels in Microglial HMC3 Cells.Lipke K, Kubis-Kubiak A, Piwowar A.Pharmaceuticals (Basel). 2023 Nov 29;16(12):1661. doi: 10.3390/ph16121661.PMID: 38139788 Free PMC article.
- MiR-155 Negatively Regulates Anti-Viral Innate Responses among HIV-Infected Progressors.Pawar P, Gokavi J, Wakhare S, Bagul R, Ghule U, Khan I, Ganu V, Mukherjee A, Shete A, Rao A, Saxena V.Viruses. 2023 Nov 1;15(11):2206. doi: 10.3390/v15112206.PMID: 38005883 Free PMC article.
- Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry.Wang H, Yang Q, Liu X, Xu Z, Shao M, Li D, Duan Y, Tang J, Yu X, Zhang Y, Hao A, Wang Y, Chen J, Zhu C, Guddat L, Chen H, Zhang L, Chen X, Jiang B, Sun L, Rao Z, Yang H.Nat Commun. 2023 Nov 21;14(1):7574. doi: 10.1038/s41467-023-42527-5.PMID: 37990007 Free PMC article.
- Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study.Chen H, Hao J, Hu J, Song C, Zhou Y, Li M, Chen J, Liu X, Wang D, Xu X, Xin P, Zhang J, Liao L, Feng Y, Li D, Pan SW, Shao Y, Ruan Y, Xing H.JMIR Public Health Surveill. 2023 Nov 17;9:e50894. doi: 10.2196/50894.PMID: 37976080 Free PMC article.
Publication types
MeSH terms
Subscribe to watch latests videos
